#FinancialStatements

In the standalone financial statements for the fiscal year ending March 2026, dividend income of JPY 48,340 million was recognized as non-operating income due to dividends paid by the consolidated subsidiary Sumitomo Pharma Switzerland GmbH.

Detailed explanation of Integral Corporation’s definition of the scope of consolidation in consolidated financial statements, methods of fair value measurement, and accounting policies including the classification of investment evaluations.